Milademetan

Generic Name: Milademetan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₃₄Cl_₂FN_₅O_₄

CAS Number: 1398568-47-2

Unique Ingredient Identifier: R3I80TLN7S

Background: Milademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset

Siremadlin plus ribociclib showed manageable safety and encouraging efficacy in MDM2/CDK4-amplified liposarcoma patients, with a median overall survival of 23 months, highlighting the potential of targeting both MDM2 and CDK4/6 pathways.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy